Hanmi Pharm Signs Fabry Disease Drug Licensing Deal With BioMarin
Hanmi Pharm, a subsidiary of Hanmi Science, signed a technology licensing agreement with BioMarin for a Fabry disease treatment.
Related stories
Warburg Pincus Announces Public Delisting Offer for PSI
Warburg Pincus announced a public acquisition offer for PSI on Oct. 20, 2026, in connection with a delisting.
M impact | MNA | Oct 30, 2026, 08:52 AM UTC
Evonik Rejects BASF Takeover Approach and Declines Negotiations
Evonik Industries said it will not enter takeover negotiations with BASF after reviewing a letter from the rival chemical company.
M impact | MNA | Oct 30, 2026, 08:38 AM UTC
Evonik Rejects Talks With BASF on Possible Takeover Offer
Evonik rejected negotiations with BASF regarding a possible takeover offer.
M impact | MNA | Oct 30, 2026, 08:17 AM UTC
Intesa Sanpaolo Makes €31 Billion Bid for MPS
The headline says the bid includes €800 million in cash and half of MPS branches going to Unipol.
M impact | MNA | Oct 30, 2026, 08:01 AM UTC
Air Liquide Cites More Than €4.1B in Investments and €2.85B DIG Airgas Deal
M impact | MNA | Oct 30, 2026, 08:01 AM UTC
Evonik to Let BASF Brief Board on Merger Rationale, Report Says
People close to Evonik say the company plans to let BASF explain the industrial logic of a merger to Evonik’s board.
M impact | MNA | Oct 30, 2026, 07:51 AM UTC